Abstract
This article reports on steps being taken to reduce publication bias in the reporting of results of clinical trials on drugs. When Bjorn Olsen of Harvard Medical School began work on the Journal of Negative Results in Biomedicine, some assumed the project was a gag. The peer-reviewed journal publishes serious research; it is just that its vision runs counter to traditional medical publishing, which tends to hide negative findings, such as a drug study that turns up adverse side effects but no measurable improvement. A group of leading journal editors announced in September a policy, effective July 2005, requiring all clinical trials to be registered from the get-go to be considered for publication in their journals. In October, six Democratic lawmakers introduced House and Senate bills that would require drug companies to register clinical trials and report results in a public database. INSET: WHEN BAD NEWS IS NO NEWS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
